A Clinical Trial Investigating Biodistribution and Shedding of an Oncolytic Virus

EBioMedicine - Netherlands
doi 10.1016/j.ebiom.2019.08.011
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Biodistribution, Shedding, and Transmissibility of the Oncolytic Virus Talimogene Laherparepvec in Patients With Melanoma

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization

Clinical Cancer Research
Cancer ResearchOncology
2006English

Oncolytic Potency and Reduced Virus Tumor-Specificity in Oncolytic Virotherapy. A Mathematical Modelling Approach

PLoS ONE
Multidisciplinary
2017English

Neural Stem Cell Tumorigenicity and Biodistribution Assessment for Phase I Clinical Trial in Parkinson’s Disease

Scientific Reports
Multidisciplinary
2016English

An Inactivated gE-deleted Pseudorabies Vaccine Provides Complete Clinical Protection and Reduces Virus Shedding Against Challenge by a Chinese Pseudorabies Variant

BMC Veterinary Research
MedicineVeterinary
2016English

Development of an Oncolytic Herpes Simplex Virus Using a Tumor-Specific HIF-responsive Promoter

Cancer Gene Therapy
Cancer ResearchMolecular MedicineMolecular Biology
2010English

Asymptomatic Shedding of Respiratory Virus Among an Ambulatory Population Across Seasons

mSphere
MicrobiologyMolecular Biology
2018English

An Oncolytic Virus Expressing a T-Cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells

Cancer Research
Cancer ResearchOncology
2018English

Bacterial-Mediated Knockdown of Tumor Resistance to an Oncolytic Virus Enhances Therapy

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy